We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) closed the most recent trading day at $244.88, moving +1.61% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.01%. Meanwhile, the Dow gained 0.14%, and the Nasdaq, a tech-heavy index, lost 0.46%.
Shares of the world's biggest maker of health care products witnessed a gain of 4.2% over the previous month, beating the performance of the Medical sector with its gain of 2.92%, and the S&P 500's loss of 1.4%.
Investors will be eagerly watching for the performance of Johnson & Johnson in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 15, 2026. The company is expected to report EPS of $2.83, up 2.17% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $25.04 billion, up 5.46% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $11.57 per share and a revenue of $100.81 billion, signifying shifts of +7.23% and +7.02%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Johnson & Johnson. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.04% lower. Johnson & Johnson presently features a Zacks Rank of #3 (Hold).
With respect to valuation, Johnson & Johnson is currently being traded at a Forward P/E ratio of 20.83. Its industry sports an average Forward P/E of 15.58, so one might conclude that Johnson & Johnson is trading at a premium comparatively.
We can also see that JNJ currently has a PEG ratio of 2.36. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.7 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 75, this industry ranks in the top 31% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow JNJ in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
Johnson & Johnson (JNJ - Free Report) closed the most recent trading day at $244.88, moving +1.61% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.01%. Meanwhile, the Dow gained 0.14%, and the Nasdaq, a tech-heavy index, lost 0.46%.
Shares of the world's biggest maker of health care products witnessed a gain of 4.2% over the previous month, beating the performance of the Medical sector with its gain of 2.92%, and the S&P 500's loss of 1.4%.
Investors will be eagerly watching for the performance of Johnson & Johnson in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 15, 2026. The company is expected to report EPS of $2.83, up 2.17% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $25.04 billion, up 5.46% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $11.57 per share and a revenue of $100.81 billion, signifying shifts of +7.23% and +7.02%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Johnson & Johnson. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.04% lower. Johnson & Johnson presently features a Zacks Rank of #3 (Hold).
With respect to valuation, Johnson & Johnson is currently being traded at a Forward P/E ratio of 20.83. Its industry sports an average Forward P/E of 15.58, so one might conclude that Johnson & Johnson is trading at a premium comparatively.
We can also see that JNJ currently has a PEG ratio of 2.36. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.7 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 75, this industry ranks in the top 31% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow JNJ in the coming trading sessions, be sure to utilize Zacks.com.